glp-1 receptor agonist manufacturers Market Size & Analysis, 2026-2033 Frontiers | GLP-1 receptor agonist

Some clinical studies have shown detrimental effects of DPP-4 inhibitors on bone [13, 16, 18], with one study showing no effects [110]

Whether you are a researcher comparing vendors or someone trying to understand this peptide before it reaches pharmacies, everything you need is here

Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, et al

Abbreviations AE: Adverse event AgRP: Agouti-related peptide ALAT: Alanine aminotransferase Anti-CGRP mAbs: Monoclonal antibodies against calcitonin gene-related peptide AP: Area postrema BMI: Body mass index CART: Cocaine- and amphetamine-regulated transcript CGRP: Calcitonin gene-related peptide CSF: Cerebrospinal fluid ENS: Enteric nervous system FUP: Follow-up GCL: Ganglion cell layer GLP-1: Glucagon-like peptide-1 GLP-1-RA: Glucagon-like peptide-1 receptor agonist Hyp: Hypothalamus ICP: Intracranial pressure IIH: Idiopathic intracranial hypertension IIH-WOP: Idiopathic intracranial hypertension without papilledema MHD: Monthly headache days NPY: Neuropeptide Y NTS: Nucleus tractus solitarii OCT: Optical coherence tomography ONSD: Optic nerve sheath diameter POMS: Proopiomelanocortin pRNFL: Peripapillary retinal nerve fiber layer pwIIH: Patients with idiopathic intracranial hypertension SFO: Subfornical organ UCWM: Usual care weight management ULN: Upper limit of normal VIIH: Vienna Idiopathic Intracranial Hypertension References Mollan SP et al (2018) Idiopathic intracranial hypertension: consensus guidelines on management

[DOI] [PubMed] [Google Scholar] 65.Bornebusch A.B., Fink-Jensen A., Wrtwein G., Seeley R.J., Thomsen M